A1M Pharma selects Research Toxicology Centre for preclinical toxicology studies on novel pre-eclampsia drug

A1M Pharma has signed an agreement with Research Toxicology Centre (RTC), a leading European contract research organisation with more than 40 years of industry experience, as its CRO partner for the company’s preclinical toxicology studies for RMC-035, the company’s lead candidate drug for pre-eclampsia based on the A1M protein.

‘It is very satisfying that we have signed an agreement with RTC as our CRO partner for the toxicology studies with our candidate drug RMC-035 to treat pre-eclampsia. We have done a very thorough evaluation of potential CRO partners, and RTC was undoubtedly the most suited partner based on our needs and specification of requirements.’

‘To get this agreement into effect and initiate the practical preparations according to plan is an important step towards our clinical phase I study,’ says A1M Pharma’s Development Manager Eddie Thordarson.

Covered in the agreement are A1M Pharma’s planned preclinical toxicology studies with the company’s candidate drug RMC-035 to treat pre-eclampsia. The agreement with RTC enables A1M Pharma to obtain the toxicity and safety data required to initiate clinical studies in humans.

Initially non-GLP studies will be conducted, which is covered within the company’s current financial framework, and then the studies will progress into the GLP phase. The estimated completion date for these studies is Q1 2017 and Q4 2017, respectively.

‘I am pleased that A1M Pharma has selected us as their CRO partner for their toxicology studies with their candidate drug RMC-035. Our extensive experience and knowledge in this area will be of great benefit for this project. We are also specifically looking forward to working with A1M Pharma in this important and exciting research area, says Germano Oberto, General Manager and Scientific Director at Research Toxicology Centre.

• X
• LinkedIn

• Companies:
• A1M Pharma

See more